Hytest Ltd.

Alexander B Postnikov

Alexey G Katrukha

Alexey V Kharitonov

Tatiana I Solovyeva

Natalia N Tamm

Tatiana I Smolyanova

Alexei G Katrukha

Alexander G Semenov

Karina R Seferyan

The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

Method for determining the risk of cardiovascular events using IGFBP fragments

Disclosed is a method for detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments. The method uses antibodies or antigen binding fragments that specifically recognize epitopes on IGFBP-4 fragments. The IGFBP-4 fragments include the N-terminal and C-terminal fragments resulting from PAPP-A dependent cleavage of IGFBP-4. Assay and diagnostic methods using detection of IGFBP-4 fragments are also disclosed.

Method for detection of IGFBP-4 fragments

The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed.

Diagnostic kit for IGFBP-4 proteolytic fragments in a patient sample

Growing community of inventors

Moscow, Russia

Alexander B Postnikov